IP Library Granted Patent US 10,179,814
Granted Patent B2
US 10,179,814 · App. 15/325,865 · Granted Jan 15, 2019

Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity

Inventors: Anette Henriksen (Alleroed, DK); Kristian Kjærgaard (Ballerup, DK); Vibeke Westphal Stennicke (Kokkedal, DK); Charlotte Wiberg (Bjärred, SE)
Assignee: Novo Nordisk A/S
C07K16/2803C07K2299/00C07K2317/55C07K2317/565C07K2317/76C07K2317/90C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,814
App. No.
15/325,865
Granted
Jan 15, 2019
Kind
B2
Abstract

Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Claims (21)

1. An antibody or fragment thereof comprising a VL and a VH, wherein the VL is a VL in a light chain selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 14 and the VH is a VH in a heavy chain selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, and SEQ ID NO: 16.

2. The antibody of claim 1 , which comprises a constant region.

3. The antibody of claim 2 , wherein the constant region is IgG1, IgG2, or IgG4.

4. The antibody of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 5 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

5. The antibody of claim 4 , which comprises a constant region of IgG4.

6. The antibody of claim 4 , which comprises a light chain and a heavy chain, wherein the light chain comprises the light chain as set forth in SEQ ID NO: 5 and the heavy chain comprises the heavy chain as set forth in SEQ ID NO: 2.

7. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 4 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

8. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 6 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

9. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 7 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

10. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 8 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

11. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 9 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

12. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 10 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

13. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 14 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 2.

14. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 5 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 15.

15. The antibody or fragment thereof of claim 1 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 14 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 16.

16. An antibody or fragment thereof comprising a VL and a VH, wherein the VL is a VL in the light chain as set forth in SEQ ID NO: 3 and the VH is a VH in a heavy chain selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, and SEQ ID NO: 16.

17. The antibody of claim 16 , which comprises a constant region.

18. The antibody of claim 17 , wherein the constant region is IgG1, IgG2, or IgG4.

19. The antibody or fragment thereof of claim 16 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 3 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 11.

20. The antibody or fragment thereof of claim 16 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 3 and a VH is the VH of the heavy chain as set forth in SEQ ID NO: 12.

21. The antibody or fragment thereof of claim 16 , wherein the VL is a VL of the light chain as set forth in SEQ ID NO: 3 and the VH is a VH of the heavy chain as set forth in SEQ ID NO: 13.

Priority Claims (2)
EP 14177547 · Jul 17, 2014 · regional
EP 14194893 · Nov 26, 2014 · regional
Continuity (1)
Related Publication 20170298130A1 · Oct 19, 2017